Skip to main content

RA Capital Management — Portfolio, Page 4

Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.

453
Companies
$44.2B
Total invested
$123.1M
Avg. check
20
Industries
Biotechnology 22Health Care 13Therapeutics 8Medical 8Life Science 7Pharmaceutical 7+14 more
Founder contacts

Verified emails & LinkedIn for founders across this portfolio.

jane@on●●●●●●●.com
linkedin.com/in/●●●●●●
Verified contacts, updated monthly
Get instant access →

Portfolio companies

Showing 7396 of 453
Artiva Biotherapeutics
May 2026

Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.

Biotechnology · San Diego$300.0M Post-IPO Equity
Avalo Therapeutics
May 2026

Avalo Therapeutics is a clinical-stage biopharmaceutical company.

Biotechnology · Rockville$431.3M Post-IPO Equity
Windward Bio
May 2026

Windward Bio develops monoclonal antibodies for advanced immunological diseases.

Biotechnology · Basel$165.0M Series B
American Express Global Corporate Travel Advisors
May 2022

American Express Global Corporate Travel Advisors provides end-to-end corporate travel and meetings program management.

Customer Service · New York$335.0M Post-IPO Equity
Exo
May 2025

Exo is a medical device startup which develops handheld ultrasound devices and AI for imaging and therapeutic applications.

Artificial Intelligence (AI) · Redwood CitySeries D
Apogee Therapeutics
May 2026

Apogee Therapeutics is a biotechnology company that offers therapies for immunological and inflammatory disorders.

Biotechnology · San Francisco$1.3B Post-IPO Debt
Secretome Therapeutics
May 2026

Secretome Therapeutics is a clinical-stage cell therapy company that develops therapies for rare cardiac diseases.

Biotechnology · Dallas$30.0M Series A
Pluton Biosciences
May 2023

Pluton Biosciences tests and discovers microbes for the production of a variety of products, primarily pesticides, and pharmaceuticals.

AgTech · Saint Louis$16.5M Series A
Icosavax
May 2023

Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.

Biotechnology · Seattle$67.8M Post-IPO Equity
cAMPfield Therapeutics
May 2026

cAMPfield Therapeutics is a biotechnology company that specializes on exploration and development activities of therapeutic solutions.

Biopharma · San Diego$180.0M Series A
Boundless Bio
May 2023

Boundless Bio is a precision oncology company that develops therapeutics directed against extrachromosomal DNA in aggressive cancers.

Biotechnology · La Jolla$100.0M Series C
Sana Biotechnology
May 2026

Sana Biotechnology is a developer of engineered cells intended to be used as medicine for patients.

Biotechnology · Seattle$69.0M Post-IPO Equity
Everest Medicines
May 2026

Everest Medicines is dedicated to its mission of developing and commercializing novel transformative pharmaceutical therapies for patients.

Biotechnology · New York$6.8M Post-IPO Secondary
Stylus Medicine
May 2025

Stylus Medicine is on a quest to create disease-treating agents for the next generation based on the groundbreaking work of its founders.

Biotechnology · Cambridge$85.0M Series A
ITeos Therapeutics
May 2024

ITeos Therapeutics is a biotechnology company that specializes in tumor immunology, cancer immunotherapy, and drug discovery.

Biotechnology · Cambridge$120.0M Post-IPO Equity
Werewolf Therapeutics
May 2022

Werewolf Therapeutics operates as an oncology biotherapeutics company.

Biotechnology · Cambridge$50.0M Post-IPO Secondary
Acrivon Therapeutics
April 2024

Acrivon Therapeutics is a precision oncology therapeutics company specializing in drug development through early clinical treatment success.

Biotechnology · Cambridge$130.0M Post-IPO Equity
Incyclix Bio
April 2026

Incyclix Bio develops small molecule inhibitors of CDKs for the treatment of advanced and resistant cancers.

Biotechnology · Durham$5.0M Series B
Stipple Bio
April 2026

Stipple Bio is a biotechnology company that offers cellular profiling and target discovery with epitope resolution.

Biopharma · Cambridge$100.0M Series A
Obsidian Therapeutics
April 2024

Obsidian Therapeutics is a developer of a next-generation cell and gene therapies created to extend adoptive immunotherapy.

Biotechnology · Cambridge$160.5M Series C
GH Research
April 2026

GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.

Biopharma · Dublin$117.5M Post-IPO Equity
Climb Bio
April 2026

Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.

Biotechnology · Redmond$110.0M Post-IPO Equity
Adela
April 2026

Adela creates develops technologies centered around detecting high-risk conditions like cancer through routine blood tests.

Biotechnology · Foster City$5.0M Convertible Note
Edgewise Therapeutics
April 2025

Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.

Biopharma · Boulder$200.0M Post-IPO Equity

Where RA Capital Management invests

Biotechnology22
Health Care13
Therapeutics8
Medical8
Life Science7
Pharmaceutical7

About RA Capital Management's portfolio

How many companies has RA Capital Management invested in?

RA Capital Management has invested in 453 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.

What industries does RA Capital Management invest in?

RA Capital Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Life Science. The firm invests across 20 different industry categories.

What is RA Capital Management's largest investment?

Among tracked funding rounds, Apogee Therapeutics received $1.3B in a Post-IPO Debt round. RA Capital Management's total known invested capital is $44.2B.

What is the average investment size for RA Capital Management?

RA Capital Management's average investment size is $123.1M across its portfolio of 453 companies.

What are RA Capital Management's most recent investments?

Recent RA Capital Management portfolio additions include Artiva Biotherapeutics, Avalo Therapeutics, Windward Bio, American Express Global Corporate Travel Advisors, Exo. These companies were founded in 2020 or later.

Reach the founders behind these 453 companies
Verified emails and LinkedIn profiles, updated monthly.
Get instant access →